| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenue | 106,592 | 713,135 | 2,661,936 | 2,863,679 |
| Cost of revenue | 204,593 | 444,177 | 1,554,159 | 1,424,392 |
| The amount of expense towards technology | - | - | 754,730 | 911,927 |
| Technology | 551,104 | 536,311 | - | - |
| Sales and marketing | 1,140,902 | 258,382 | 631,625 | 1,082,949 |
| Supply development | 22,373 | 99,090 | 84,972 | 137,511 |
| Fulfillment | 153,781 | 248,225 | 449,142 | 433,189 |
| General and administrative | 864,061 | 948,376 | 892,712 | 1,055,376 |
| Total operating expenses | 2,936,814 | 2,534,561 | 4,367,340 | 5,045,344 |
| Loss from operations | -2,830,222 | -1,821,426 | -1,705,404 | -2,181,665 |
| Interest expense | 2 | 0 | - | - |
| Interest income | 291 | 398 | - | - |
| Interest and penalties on sales tax liability | -2,069 | -9,620 | - | - |
| Other income, net | 47,216 | 764,165 | 271,680 | 67,952 |
| Interest income, other | - | - | 1,235 | 9,163 |
| Interest expense | - | - | 7,364 | 4,474 |
| Total other income, net | 49,574 | 774,183 | 265,551 | 72,641 |
| Net loss | -2,780,648 | -1,047,243 | -1,439,853 | -2,109,024 |
| Unrealized loss on available-for-sale securities | - | 0 | - | - |
| Total other comprehensive loss | - | 0 | - | - |
| Comprehensive loss | -2,780,648 | -1,047,243 | - | - |
| Net loss per share - basic (in dollars per share) | -0.48 | -0.42 | -2.1 | -0.19 |
| Net loss per share - diluted (in dollars per share) | -0.48 | -0.42 | -2.1 | - |
| Weighted average shares of common stock outstanding - basic (in shares) | 5,839,580 | 2,496,860 | 687,141 | 11,340,586 |
| Weighted average shares of common stock outstanding - diluted (in shares) | 5,839,580 | 2,496,860 | 687,141 | - |
iSpecimen Inc. (ISPC)
iSpecimen Inc. (ISPC)